![[Preprint] RECOVERY trial finds Regeneron’s monoclonal antibody combination reduces deaths for hospitalized COVID-19 patients who have not mounted their own immune response.](/media/k2/items/cache/e9ade54bcd41c186f40b423e5c4dc324_L.jpg)
[Preprint] RECOVERY trial finds Regeneron’s monoclonal antibody combination reduces deaths for hospitalized COVID-19 patients who have not mounted their own immune response.
News release: RECOVERY trial finds Regeneron’s monoclonal antibody combination reduces deaths for hospitalised COVID-19 patients who have not mounted their own immune response Original study (preprint): Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial – medRxiv Commentaries: Monoclonal antibodies cut risk of dying from COVID-19—but only […]
The post [Preprint] RECOVERY trial finds Regeneron’s monoclonal antibody combination reduces deaths for hospitalized COVID-19 patients who have not mounted their own immune response. appeared first on Links Medicus.
-
Taille de police
Réduire la taille de la police
Augmenter la taille de police
About Author
Dernier de Zouhair Souissi
- Summary: Perioperative Management of Patients Taking Direct Oral Anticoagulants
- Summary: Community-Acquired Pneumonia
- RCT: Twice-Yearly Depemokimab Reduced Exacerbations in Severe Eosinophilic Asthma
- RCT: High-Intensity NPPV Reduced Criteria for Intubation in Acute COPD Exacerbations
- M-A | Routine anaerobic coverage for aspiration pneumonia: limited evidence of benefit
Laissez un commentaire
Assurez-vous d'entrer toutes les informations requises, indiquées par un astérisque (*). Le code HTML n'est pas autorisé.